INVO Bioscience, Inc. announced the appointment of two seasoned executives, Barbara Ryan and Matthew Szot, to its board of directors, effective immediately. To make way for their appointments, Kathleen Karloff and Michael Campbell have both agreed to voluntarily step down from their board positions to assist the company in achieving an independent board majority. Mr. Campbell will remain as Chief Operating Officer and Vice President of Business Development, while Ms. Karloff intends to continue to advise the board and assist the operating team on a go forward basis. In connection with the appointments of Ms. Ryan and Mr. Szot, along with existing independent board member, Trent Davis, Independent directors now comprise the majority of Board and the company has established all of the key required board committees, including Audit, Compensation, and Nominating and Corporate Governance. All three of the independent directors will be members of each committee, with Mr. Szot chairing the Audit and Compensation Committees and Mr. Davis chairing the Nominating and Corporate Governance Committee. Ms. Ryan founded Barbara Ryan Advisors, a capital markets and communications firm, in 2012 following a more than 30-year career on Wall Street as a sell-side research analyst covering the US Large Cap Pharmaceutical Industry. Previously, Ms. Ryan was a Managing Director at Deutsche Bank/Alex Brown and Head of the company's Pharmaceutical Research Team for 19 years and began her research career covering the Pharmaceutical industry at Bear Stearns in 1982. Ms. Ryan has extensive global buyside, sell side and financial media relationships, and has provided support and counsel on several of the highest profile deals in the biopharma industry, including Shire/Abbvie, Shire/Baxalta, and Allergan/Valeant. Barbara led the IR/PR programs for Radius Health, the best performing IPO of 2014, for 4 years, Eloxx Pharmaceuticals for the past two years and served on the Executive Team at both companies. Mr. Szot is currently the Executive Vice President and Chief Financial Officer of S&W Seed Company where he has served since March 2010. Mr. Szot also serves on the board of directors and as Chairman of the Audit Committee of SenesTech. From 2007 until 2011, Mr. Szot served as the Chief Financial Officer for Cardiff Partners, LLC, a strategic consulting company that provided executive financial services to various publicly traded and privately held companies.
INVO Bioscience, Inc. is a healthcare services fertility company. The Company is focused on expanding the assisted reproductive technology (ART) marketplace by making fertility care accessible and inclusive to people around the world. The Companyâs flagship product is INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the womanâs body. Its treatment solution is the intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo development. Its technique, designated as IVC, provides patients a more connected and intimate experience at a more affordable cost in comparison to in vitro fertilization (IVF), the other advanced ART treatment. Its commercialization strategy is focused on the opening of INVO Centers offering the INVOcell and IVC procedure and the acquisition of existing IVF clinics. The Company operates three INVO Centers in North America.
INVO BIOSCIENCE, INC. 
